NL301128I2 - Risdiplam of een farmaceutisch aanvaardbaar zout daarvan - Google Patents
Risdiplam of een farmaceutisch aanvaardbaar zout daarvanInfo
- Publication number
- NL301128I2 NL301128I2 NL301128C NL301128C NL301128I2 NL 301128 I2 NL301128 I2 NL 301128I2 NL 301128 C NL301128 C NL 301128C NL 301128 C NL301128 C NL 301128C NL 301128 I2 NL301128 I2 NL 301128I2
- Authority
- NL
- Netherlands
- Prior art keywords
- risdiplam
- pharmaceutically acceptable
- acceptable salt
- salt
- pharmaceutically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 | |
| PCT/EP2015/060343 WO2015173181A1 (en) | 2014-05-15 | 2015-05-11 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301128I1 NL301128I1 (nl) | 2021-09-22 |
| NL301128I2 true NL301128I2 (nl) | 2021-10-25 |
Family
ID=53175048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301128C NL301128I2 (nl) | 2014-05-15 | 2021-09-15 | Risdiplam of een farmaceutisch aanvaardbaar zout daarvan |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (nl) |
| EP (3) | EP3143025B1 (nl) |
| JP (1) | JP6236173B2 (nl) |
| KR (2) | KR102256013B1 (nl) |
| CN (1) | CN106459092B (nl) |
| AR (1) | AR100442A1 (nl) |
| AU (1) | AU2015261046C1 (nl) |
| CA (1) | CA2948561C (nl) |
| CL (1) | CL2016002836A1 (nl) |
| CR (1) | CR20160518A (nl) |
| DK (1) | DK3143025T3 (nl) |
| EA (2) | EA202090486A3 (nl) |
| ES (2) | ES2949660T3 (nl) |
| FR (1) | FR21C1039I2 (nl) |
| HR (2) | HRP20230637T1 (nl) |
| HU (2) | HUE046491T2 (nl) |
| IL (2) | IL248653B (nl) |
| LT (1) | LTPA2021010I1 (nl) |
| MA (2) | MA39995B1 (nl) |
| MX (1) | MX371050B (nl) |
| MY (1) | MY174284A (nl) |
| NL (1) | NL301128I2 (nl) |
| NO (1) | NO2021035I1 (nl) |
| NZ (1) | NZ725008A (nl) |
| PE (1) | PE20170128A1 (nl) |
| PH (1) | PH12016502081A1 (nl) |
| PL (2) | PL3663296T3 (nl) |
| PT (1) | PT3143025T (nl) |
| RS (1) | RS59718B1 (nl) |
| SG (1) | SG11201609497TA (nl) |
| SI (2) | SI3143025T1 (nl) |
| TW (1) | TWI667239B (nl) |
| UA (1) | UA119670C2 (nl) |
| WO (1) | WO2015173181A1 (nl) |
| ZA (1) | ZA201607026B (nl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037123B1 (ru) | 2012-02-10 | 2021-02-09 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| JP6749343B2 (ja) | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| CN108137601A (zh) * | 2015-11-12 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 用于治疗肌萎缩性侧索硬化症的化合物 |
| JP6659841B2 (ja) * | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| LT3386511T (lt) | 2015-12-10 | 2021-08-25 | Ptc Therapeutics, Inc. | Hantingtono ligos gydymo būdai |
| AU2017363369A1 (en) * | 2016-11-28 | 2019-05-30 | Ptc Therapeutics, Inc | Methods for modulating RNA splicing |
| IL300875A (en) | 2017-06-05 | 2023-04-01 | Ptc Therapeutics Inc | Compounds for the treatment of Huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| US11395822B2 (en) | 2017-06-28 | 2022-07-26 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| EP3684766A1 (en) * | 2017-09-22 | 2020-07-29 | H. Hoffnabb-La Roche Ag | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| JP7423515B2 (ja) * | 2017-10-03 | 2024-01-29 | エフ． ホフマン－ラ ロシュ アーゲー | Ｓｍａの新たな処置 |
| WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| KR20210079317A (ko) | 2018-10-19 | 2021-06-29 | 에프. 호프만-라 로슈 아게 | 피리도[1,2-a]피리미딘-4-온 유도체의 형태, 그의 제형 및 그의 제조 방법 |
| CN113966219A (zh) | 2019-06-12 | 2022-01-21 | 豪夫迈·罗氏有限公司 | Sma的新治疗方法 |
| US20220315607A1 (en) | 2019-07-31 | 2022-10-06 | Teva Pharmaceuticals International Gmbh | Solid state forms of risdiplam and process for preparation thereof |
| WO2022048675A1 (zh) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Risdiplam晶型及其制备方法和用途 |
| WO2022162107A1 (en) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Crystalline form of risdiplam |
| KR20230157367A (ko) | 2021-03-17 | 2023-11-16 | 에프. 호프만-라 로슈 아게 | 신규 티아졸로피리미디논 유도체 |
| CN116981673A (zh) * | 2021-03-17 | 2023-10-31 | 豪夫迈·罗氏有限公司 | 新颖噻二唑并嘧啶酮衍生物 |
| BR112023018593A2 (pt) | 2021-03-18 | 2023-10-24 | Hoffmann La Roche | Processo |
| WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024081932A1 (en) | 2022-10-14 | 2024-04-18 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69719193T2 (de) * | 1996-08-06 | 2003-09-25 | Pfizer | Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate |
| WO2009042907A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| KR20100012134A (ko) * | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| JP2011529722A (ja) * | 2008-08-14 | 2011-12-15 | カーディアック ペースメイカーズ， インコーポレイテッド | 音響通信リンクの性能評価および適合 |
| BR112014016287B1 (pt) * | 2011-12-30 | 2022-08-09 | F. Hoffmann - La Roche Ag | Composto e composição farmacêutica |
| EA037123B1 (ru) * | 2012-02-10 | 2021-02-09 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| EP2872493B1 (en) | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
-
2015
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/en active Active
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/en active Pending
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 CA CA2948561A patent/CA2948561C/en active Active
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active IP Right Grant
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active IP Right Grant
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/en active Application Filing
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/en active Active
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-19 PH PH12016502081A patent/PH12016502081A1/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
- 2019-11-29 HR HRP20192159TT patent/HRP20192159T1/hr unknown
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-14 LT LTPA2021010C patent/LTPA2021010I1/lt unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301111I2 (nl) | Entrectinib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301128I2 (nl) | Risdiplam of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301253I2 (nl) | mavacamten of een farmaceutisch aanvaardbaar zout daarvan | |
| NO2022046I1 (no) | Berotralstat and pharmaceutically acceptable salts thereof | |
| NO2022009I1 (no) | Lumasiran, optionally in the form of a salt | |
| NL301224I2 (nl) | Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NO2024007I1 (no) | Elacestrant or a salt thereof | |
| DK3125836T3 (da) | Vejrtrækningshjæpeapparat | |
| FIC20240006I1 (fi) | Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola | |
| DK3220989T3 (da) | Intranasal administration | |
| DK3188724T3 (da) | Liposom-indkapslet affinitetsmedikament | |
| NL301061I2 (nl) | givosiran of een farmaceutisch aanvaardbaar zout daarvan | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3131898T3 (da) | Fluoroalkylfluorenderivativer | |
| DE112015002984A5 (de) | Positioniereinheit | |
| DK3191067T3 (da) | En farmaceutisk pakning | |
| BR112017008876A2 (pt) | novas piridilamidinas fungicidas | |
| DK3453388T3 (da) | Farmaceutisk opløsning omfattende dopaminhydrochlorid | |
| DK3206821T3 (da) | Hulfrembringelsessystem | |
| FR3028902B1 (fr) | Palier a roulement | |
| DE112014006602A5 (de) | Positioniersystem | |
| DK3193923T3 (da) | Adjuvanser | |
| UA31168S (uk) | Інгалятор | |
| UA30864S (uk) | Інгалятор |